XML 26 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrant Liabilities
6 Months Ended
Jun. 30, 2016
Warrant Liabilities [Abstract]  
Warrant Liabilities
8.               Warrant Liabilities
Liabilities measured at fair value on a recurring basis include warrant liabilities resulting from our equity financings.  In accordance with ASC 815-40, Derivatives and Hedging – Contracts in Entity's Own Equity ("ASC 815-40"), the warrant liabilities are recorded at fair value until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company's application of ASC 505-50, Equity-Based Payments to Non-Employees ("ASC 505-50"). The gain or loss resulting from the change in fair value is shown on the Condensed Statements of Operations as gain (loss) on warrant derivative liability. We recognized a gain of $0.9 million and $2.4 million for the three-month periods ended June 30, 2016 and 2015, respectively, and a gain of $0.7 million and $0.6 million for the six-month periods ended June 30, 2016 and 2015, respectively. The following reflects the weighted-average assumptions for each of the six-month periods indicated:
 
  
Six Months Ended June 30,
 
  
2016
  
2015
 
       
Risk-free interest rate
  
0.20
%
  
0.28
%
Expected dividend yield
  
0
%
  
0
%
Expected lives
  
0.09
   
1.09
 
  Expected volatility
  
59.3
%
  
62.7
%
  Warrants classified as liabilities (in shares)
  
6,371,854
   
6,371,854
 
         
Our computation of expected volatility is based on the historical daily volatility of its publicly traded stock. The dividend yield assumption of zero is based upon the fact that we have never paid cash dividends and presently have no intention to do so.  The risk-free interest rate used for each warrant classified as a derivative is equal to the U.S. Treasury rates in effect at June 30 of each year presented. The expected lives are based on the remaining contractual lives of the related warrants at the valuation date.
On August 1, 2016, these warrants expire.